Aflac (AFL) Stock Looks Below Fair Value Even After A 135% Run
Aflac stock has delivered a strong 5 year run, yet the current market price and the valuation checks do not line up cleanly. The Excess Returns intrinsic value estimate points to meaningful upside, while earnings based multiples lean rich for this insurer.
- Aflac has returned 134.9% over 5 years, which sets a high bar for any new upside case built on valuation alone.
- Future cash generation from Aflac's insurance book can support the intrinsic value case. However, any pressure on underwriting profitability or investment income may undermine it.
- The broader valuation score is mixed, with 3 out of 6 checks suggesting Aflac is not a clear bargain or clearly overpriced.
The stock's next move may depend on whether the market ultimately leans toward the intrinsic value estimate or the richer picture implied by current market multiples.
Compare Aflac's valuation puzzle with a curated set of insurers and financials that currently screen as potentially mispriced using 33 high quality undervalued stocks.
Does Aflac Look Undervalued on Excess Returns?
The Excess Returns model starts from a simple idea. Aflac creates value when the profit on its equity base beats the return investors demand.
In this framework, Aflac is treated as a mature insurer with steady profitability rather than a high growth story. Book value sits at $60.35 per share and is expected to edge toward a stable $62.13, while stable EPS of $8.29 per share implies an average return on equity of 13.34%. Against a cost of equity of $4.50 per share, the model attributes $3.79 per share to excess profit on that capital, which compounds as the balance sheet expands.
Using these inputs in the Excess Returns framework produces an intrinsic value estimate of $169.38 per share. That figure is 32.4% above the current market price implied by the model, which points to a gap between the earnings power of Aflac’s equity base and how the stock is currently priced.
On this measure, Aflac stock appears undervalued relative to the excess returns it is projected to generate on its capital base.
Our Excess Returns analysis suggests Aflac is undervalued by 32.4%. Track this in your watchlist or portfolio, or discover 33 more high quality undervalued stocks.
Has Aflac Run Too Far on Earnings?
P/E fits Aflac well because earnings remain a primary reference point for how investors appraise an established insurer.
Aflac trades on a P/E of 11.8x, which is slightly above the Insurance sector average of 11.2x and below the peer group average of 16.4x. The tailored fair P/E from the model sits at 9.7x, suggesting the current earnings multiple embeds a premium to what those fundamentals and risk inputs would typically support. That gap indicates investors are paying up compared with this framework even though the sector benchmark itself is not especially stretched.
The stock still prices in a richer earnings tag than the model’s fair P/E would point to, even after allowing for industry context and peer comparisons.
On this P/E yardstick, Aflac stock screens as overvalued relative to the earnings profile implied by the fair multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The Aflac Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Aflac pick up where this valuation split leaves off. They spell out which assumptions on Aflac's growth, margins and earnings would need to hold for the shares to be worth materially more or less than today. Each scenario anchors a fair value to a clear story about potential drivers and threats, which lets you track over time which version of events seems to be taking shape on the Community page.
Use this split view on Aflac's value as a springboard to add your own narrative on where its growth, margins and execution go from here. Share a number-driven case, and be one of the first voices in the Simply Wall St community tracking how that thesis holds up as new results arrive.
Do you think there's more to the story for Aflac? Head over to our Community to see what others are saying!
The Bottom Line
Aflac screens as undervalued on the Excess Returns intrinsic value estimate, yet the P/E work suggests the shares trade on a richer multiple than the model deems comfortable. That split largely reflects different emphases, with the intrinsic view focused on the durability of cash generation and the multiple view keyed to how much investors are already paying for that earnings profile. The crux from here is whether Aflac can sustain returns on equity and underwriting discipline strongly enough for the cash driven valuation to matter more than the premium earnings tag.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com